LT5011B - Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip hormonų pakeitimo terapijos (hpt) kompozicijų komponentai - Google Patents

Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip hormonų pakeitimo terapijos (hpt) kompozicijų komponentai Download PDF

Info

Publication number
LT5011B
LT5011B LT2002037A LT2002037A LT5011B LT 5011 B LT5011 B LT 5011B LT 2002037 A LT2002037 A LT 2002037A LT 2002037 A LT2002037 A LT 2002037A LT 5011 B LT5011 B LT 5011B
Authority
LT
Lithuania
Prior art keywords
estrogen
mesoprogestin
mesoprogestins
progesterone
estradiol
Prior art date
Application number
LT2002037A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002037A (en
Inventor
Walter Elger
Kristof Chwalisz
Gerd SCHUBERT
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of LT2002037A publication Critical patent/LT2002037A/xx
Publication of LT5011B publication Critical patent/LT5011B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT2002037A 1999-08-31 2002-03-27 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip hormonų pakeitimo terapijos (hpt) kompozicijų komponentai LT5011B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614099A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002037A LT2002037A (en) 2002-11-25
LT5011B true LT5011B (lt) 2003-04-25

Family

ID=23524333

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002037A LT5011B (lt) 1999-08-31 2002-03-27 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip hormonų pakeitimo terapijos (hpt) kompozicijų komponentai

Country Status (33)

Country Link
EP (1) EP1605924B1 (sl)
JP (1) JP2003513908A (sl)
KR (1) KR100729311B1 (sl)
CN (1) CN1454088A (sl)
AR (1) AR025456A1 (sl)
AT (1) ATE413168T1 (sl)
AU (1) AU781836B2 (sl)
BG (1) BG65846B1 (sl)
BR (1) BR0013710A (sl)
CA (1) CA2383659C (sl)
CO (1) CO5200773A1 (sl)
CZ (1) CZ301412B6 (sl)
DE (1) DE60040764D1 (sl)
EA (1) EA007840B1 (sl)
EE (1) EE200200102A (sl)
ES (1) ES2316402T3 (sl)
HR (1) HRP20020266A2 (sl)
HU (1) HUP0202460A3 (sl)
IL (2) IL148417A0 (sl)
LT (1) LT5011B (sl)
LV (1) LV12942B (sl)
MX (1) MXPA02002190A (sl)
NO (1) NO20021000L (sl)
NZ (1) NZ517469A (sl)
PE (1) PE20010581A1 (sl)
PL (1) PL198798B1 (sl)
RO (1) RO122180B1 (sl)
RS (1) RS50396B (sl)
SI (1) SI20851B (sl)
SK (1) SK287121B6 (sl)
UA (1) UA75339C2 (sl)
WO (1) WO2001034126A2 (sl)
ZA (1) ZA200201621B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
DE50304970D1 (de) * 2002-08-02 2006-10-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2611370C1 (ru) * 2016-01-12 2017-02-21 Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" Применение препарата Лаеннек для уменьшения или устранения проявления менопаузальных симптомов (варианты)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
US2156599A (en) 1936-11-20 1939-05-02 Soc Of Chemical Ind Estradiol esters esterified in 3-position and process of making same
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
EP0178862A2 (en) 1984-10-12 1986-04-23 BCM Technologies, INC. Antiestrogen therapy for symptoms of estrogen deficiency
WO1993017686A1 (en) 1992-03-02 1993-09-16 Schering Aktiengesellschaft Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
WO1994003408A1 (de) 1992-08-03 1994-02-17 Karl Hehl Verfahren zur herstellung von pulverförmigen massen für das spritzgiessen keramischer materialien und deren verwendung
WO1994018983A1 (en) 1993-02-25 1994-09-01 The Medical College Of Hampton Roads Hormone replacement therapy
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5393763A (en) 1992-07-28 1995-02-28 Eli Lilly And Company Methods for inhibiting bone loss
DE4332284A1 (de) 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1997033589A1 (de) 1996-03-11 1997-09-18 Schering Aktiengesellschaft Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283662B6 (sk) * 1994-10-24 2003-11-04 Schering Aktiengesellschaft Kompetetívne progesterónantagonisty na kontrolu samičej fertility zameranú podľa potreby
JP2000514785A (ja) * 1996-06-25 2000-11-07 アクゾ・ノベル・エヌ・ベー プロゲストゲン―抗プロゲストゲン処方
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1144396A2 (en) * 1999-01-14 2001-10-17 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
US2156599A (en) 1936-11-20 1939-05-02 Soc Of Chemical Ind Estradiol esters esterified in 3-position and process of making same
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
EP0178862A2 (en) 1984-10-12 1986-04-23 BCM Technologies, INC. Antiestrogen therapy for symptoms of estrogen deficiency
WO1993017686A1 (en) 1992-03-02 1993-09-16 Schering Aktiengesellschaft Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses
US5393763A (en) 1992-07-28 1995-02-28 Eli Lilly And Company Methods for inhibiting bone loss
WO1994003408A1 (de) 1992-08-03 1994-02-17 Karl Hehl Verfahren zur herstellung von pulverförmigen massen für das spritzgiessen keramischer materialien und deren verwendung
WO1994018983A1 (en) 1993-02-25 1994-09-01 The Medical College Of Hampton Roads Hormone replacement therapy
DE4332284A1 (de) 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
WO1997033589A1 (de) 1996-03-11 1997-09-18 Schering Aktiengesellschaft Sequentielle estrogen/progesteronantagonist-kombination für die hormonersatz-therapie

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BUCKLEY MM, GOA KL.: "Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use", DRUGS, 1989, pages 451 - 490
ELGER W ET AL.: "Studies on the mechanisms of action of progesterone antagonists", J STEROID BIOCHEM., 1986, pages 835 - 845, XP023414415, DOI: doi:10.1016/0022-4731(86)90314-6
ERNSTER VLET AL.: "Benefits and risks of menopausal estrogen and/or progestin hormone use", PREV MED., 1988, pages 201 - 223, XP026323750, DOI: doi:10.1016/0091-7435(88)90064-3
H. SELYE ET AL.: "Textbook of Endocrinology", pages: 345 - 346
HILLARD TC ET AL.: "Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis", AM J OBSTET GYNECOL., 1992, pages 1 - 7
J. A. STAFFA ET AL.: "Progestins and Breast Cancer: An Epidemiologic Review", FERTIL STERIL., 1992, pages 473 - 491
LOVE RR ET AL.: "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer", N ENGL J MED., 1992, pages 852 - 856, XP000978436
R. J. B. KING: "A Discussion of the Roles of Estrogen and Progestin in Human Mammary Carcinogenesis", J STEROID BIOCHEM MOL BIOL., 1991, pages 8111 - 8118
R. LOBO: "The Role of Progestins in Hormone Replacement Therapy", AM. J. OBSTET. GYNECOL., 1992, pages 1997 - 2004, XP000886718
T. FORNANDER: "Adjuvant Tamoxifen in Early Breast Cancer: Occurrence of New Primary Cancers", LANCET, 1989, pages 117 - 119
W. E. GIBBSON: "Biochemical and Histological Effects of Sequential Estrogen/Progestin Therapy on the Endometrium of Postmenopausal Women", AM. J. OBSTET. GYNECOL., 1986, pages 46 - 61

Also Published As

Publication number Publication date
CA2383659C (en) 2009-02-10
ATE413168T1 (de) 2008-11-15
NO20021000D0 (no) 2002-02-28
CZ2002706A3 (cs) 2002-10-16
AU781836B2 (en) 2005-06-16
HRP20020266A2 (en) 2004-08-31
SK287121B6 (sk) 2009-12-07
AR025456A1 (es) 2002-11-27
IL148417A0 (en) 2002-09-12
SI20851B (sl) 2009-06-30
HUP0202460A2 (hu) 2002-12-28
WO2001034126A2 (en) 2001-05-17
UA75339C2 (en) 2006-04-17
DE60040764D1 (de) 2008-12-18
CO5200773A1 (es) 2002-09-27
YU14102A (sh) 2006-01-16
WO2001034126A9 (en) 2002-09-12
KR100729311B1 (ko) 2007-06-19
EA200200285A1 (ru) 2002-08-29
NZ517469A (en) 2004-01-30
BG65846B1 (bg) 2010-03-31
CA2383659A1 (en) 2001-05-17
SK2972002A3 (en) 2002-07-02
CN1454088A (zh) 2003-11-05
ZA200201621B (en) 2004-08-25
AU3633201A (en) 2001-06-06
WO2001034126A3 (en) 2001-11-22
SI20851A (sl) 2002-10-31
KR20020027618A (ko) 2002-04-13
RS50396B (sr) 2009-12-31
EP1605924A2 (en) 2005-12-21
LT2002037A (en) 2002-11-25
PL353931A1 (en) 2003-12-15
RO122180B1 (ro) 2009-02-27
EP1605924B1 (en) 2008-11-05
ES2316402T3 (es) 2009-04-16
IL148417A (en) 2010-11-30
JP2003513908A (ja) 2003-04-15
LV12942B (en) 2003-06-20
HUP0202460A3 (en) 2004-04-28
PE20010581A1 (es) 2001-06-04
MXPA02002190A (es) 2002-09-30
NO20021000L (no) 2002-03-14
BR0013710A (pt) 2002-05-07
EA007840B1 (ru) 2007-02-27
EE200200102A (et) 2003-04-15
PL198798B1 (pl) 2008-07-31
CZ301412B6 (cs) 2010-02-24
BG106443A (bg) 2002-09-30

Similar Documents

Publication Publication Date Title
KR100348116B1 (ko) 폐경기 및 폐경후 여성을 위한 호르몬 대체 요법에사용하기위한프로게스테론길항제및부분적아고니스트작용을갖는항에스트로겐제의조합
CZ195397A3 (en) Progesteron antagonistically and antiestrogenic active compounds for common use for woman contraception
CA2383659C (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
BG106441A (bg) Мезопрогестини (модулатори на прогестероновия рецептор) като компоненти на женски контрацептиви
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
AU5942700A (en) Sequential estrogen/progestrone antagonist combination for hormone replacement theapy

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20050104

MM9A Lapsed patents

Effective date: 20100831